Critical Survey: Talphera (TLPH) and Its Competitors

Talphera (NASDAQ:TLPHGet Free Report) is one of 973 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Talphera to related companies based on the strength of its dividends, profitability, analyst recommendations, risk, earnings, institutional ownership and valuation.

Analyst Recommendations

This is a breakdown of recent ratings for Talphera and its competitors, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Talphera 0 0 1 0 3.00
Talphera Competitors 5938 17474 41535 842 2.57

Talphera presently has a consensus price target of $6.00, indicating a potential upside of 445.45%. As a group, “Pharmaceutical preparations” companies have a potential upside of 81.64%. Given Talphera’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Talphera is more favorable than its competitors.


This table compares Talphera and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Talphera N/A -81.54% -46.02%
Talphera Competitors -1,995.60% -236.15% -30.61%

Insider & Institutional Ownership

19.8% of Talphera shares are held by institutional investors. Comparatively, 39.5% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 3.0% of Talphera shares are held by company insiders. Comparatively, 14.7% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Talphera and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Talphera $1.77 million $47.76 million -0.49
Talphera Competitors $8.88 billion $172.63 million -1.58

Talphera’s competitors have higher revenue and earnings than Talphera. Talphera is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

Talphera has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Comparatively, Talphera’s competitors have a beta of 0.78, indicating that their average share price is 22% less volatile than the S&P 500.


Talphera competitors beat Talphera on 7 of the 13 factors compared.

Talphera Company Profile

(Get Free Report)

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. Talphera, Inc. was incorporated in 2005 and is headquartered in San Mateo, California.

Receive News & Ratings for Talphera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talphera and related companies with's FREE daily email newsletter.